Avita MedicalRCEL
About: Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Employees: 260
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
109% more call options, than puts
Call options by funds: $557K | Put options by funds: $266K
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
23% more capital invested
Capital invested by funds: $65.7M [Q3] → $80.5M (+$14.8M) [Q4]
6% more funds holding
Funds holding: 67 [Q3] → 71 (+4) [Q4]
0.42% more ownership
Funds ownership: 23.58% [Q3] → 24.0% (+0.42%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
D. Boral Capital Jason Kolbert 36% 1-year accuracy 85 / 239 met price target | 126%upside $22 | Buy Maintained | 20 Feb 2025 |
Lake Street Brooks O'Neil 43% 1-year accuracy 6 / 14 met price target | 44%upside $14 | Buy Maintained | 8 Jan 2025 |
Cantor Fitzgerald Ross Osborn 59% 1-year accuracy 27 / 46 met price target | 115%upside $21 | Overweight Reiterated | 24 Dec 2024 |
Financial journalist opinion
Based on 5 articles about RCEL published over the past 30 days
